Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Anchorage Radiation Therapy Center — Anchorage, Alaska
+ 952 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Locations: - Cancer Center at Saint Joseph's — Phoenix, Arizona
- Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- Mercy Hospital Fort Smith — Fort Smith, Arkansas
+ 649 more sites in the U.S.
Phase 3 Recruiting Industry
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…
Sponsor: Gilead Sciences
NCT ID: NCT05633654
Locations: - Alabama Oncology — Birmingham, Alabama
- Clearview Cancer Institute — Huntsville, Alabama
- Palo Verde Hematology Oncology — Glendale, Arizona
+ 181 more sites in the U.S.
Phase 3 Recruiting Industry
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early b…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06492616
Locations: - Southern Cancer Center, PC — Daphne, Alabama
- Ironwood Cancer and Research Centers — Chandler, Arizona
- Banner MD Anderson Cancer Center — Gilbert, Arizona
+ 162 more sites in the U.S.
Phase 3 Recruiting Industry
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…
Sponsor: AstraZeneca
NCT ID: NCT06103864
Locations: - Research Site — Daphne, Alabama
- Research Site — Springdale, Arkansas
- Research Site — Duarte, California
+ 61 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…
Sponsor: NRG Oncology
NCT ID: NCT06500481
Locations: - Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- UC San Diego Health System - Encinitas — Encinitas, California
+ 55 more sites in the U.S.
Phase 3 Recruiting Industry
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06790693
Locations: - The Dignity Health Cancer Institute — Phoenix, Arizona
- Disney Family Cancer Center — Burbank, California
- Scripps Health — La Jolla, California
+ 48 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-pa…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06926868
Locations: - Local Institution - 0303 — Hot Springs, Arkansas
- Helios Clinical Research — Cerritos, California
- Local Institution - 0307 — Cerritos, California
+ 43 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…
Sponsor: AstraZeneca
NCT ID: NCT06952803
Locations: - Research Site — Phoenix, Arizona
- Research Site — Tucson, Arizona
- Research Site — La Jolla, California
+ 39 more sites in the U.S.
Phase 3 Recruiting Industry
This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after…
Sponsor: Hoffmann-La Roche
NCT ID: NCT05894239
Locations: - Banner Health MD Anderson AZ — Gilbert, Arizona
- Disney Family Cancer Center — Burbank, California
- City of Hope — Corona, California
+ 17 more sites in the U.S.
Phase 3 Recruiting Academic/Other
The purpose of this study is to compare using FDA-approved bupivacaine (a numbing medicine), along with the usual medications for post-operative pain control to using the usual medications for postoperative pain control alone. The addition…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT03351348
Locations: - Memorial Sloan Kettering Basking Ridge (Consent and follow-up only) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Consent and follow-up only) — Montvale, New Jersey
+ 4 more sites in the U.S.
Phase 3 Recruiting Academic/Other
The trial aims to investigate the use of superparamagnetic iron oxide (SPIO) nanoparticles as a tracer for delayed sentinel lymph node dissection (d-SLND) in patients where upfront axillary surgery (SLND) is oncologically deemed unnecessar…
Sponsor: Uppsala University
NCT ID: NCT04722692
Locations: - Baylor College Of Medicine — Houston, Texas